The first 99mTc and 188Re radiopharmaceuticals containing two pendant bisphosphonate groups has been synthesised, based on the mononuclear M(V) nitride core with two dithiocarbamate ligands each with a pendant bisphosphonate. The structural identity of the 99Tc and stable rhenium analogues as uncharged, mononuclear nitridobis(dithiocarbamate) complexes was determined by electrospray mass spectrometry. The 99mTc complex showed greater affinity for synthetic and biological hydroxyapatite, and greater stability in biological media than the well-known but poorly characterised and inhomogeneous bone imaging agent 99mTc-MDP. It gave excellent SPECT images of both bone calcification (mice and rats) and vascular calcification (rat model), but the improved stability and the availability of two pendant bisphosphonate groups conferred no dramatic advantage over the conventional 99mTc-MDP agent in which the bisphosphonate group is bound directly to Tc. The 188Re complex also showed preferential uptake in bone. These tracers and the biological model of vascular calcification offer the opportunity to study the biological interpretation and clinical potential of radionuclide imaging of vascular calcification and to deliver radionuclide therapy to bone metastases.